U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Hypopharyngeal Squamous Cell Carcinoma

MedGen UID:
1777191
•Concept ID:
C5419759
•
Neoplastic Process

Definition

Hypopharyngeal squamous cell carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Hypopharyngeal Squamous Cell Carcinoma

Professional guidelines

PubMed

Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S, Kato K
Expert Opin Biol Ther 2020 Oct;20(10):1143-1150. Epub 2020 Jul 14 doi: 10.1080/14712598.2020.1792881. PMID: 32620063
Neck management in head and neck squamous cell carcinomas: where do we stand?
Klausner G, Troussier I, Blais E, Carsuzaa F, Zilli T, Miralbell R, Caparrotti F, Thariat J
Med Oncol 2019 Mar 27;36(5):40. doi: 10.1007/s12032-019-1265-1. PMID: 30919135
Japanese Clinical Practice Guideline for Head and Neck Cancer.
Nibu KI, Hayashi R, Asakage T, Ojiri H, Kimata Y, Kodaira T, Nagao T, Nakashima T, Fujii T, Fujii H, Homma A, Matsuura K, Monden N, Beppu T, Hanai N, Kirita T, Kamei Y, Otsuki N, Kiyota N, Zenda S, Omura K, Omori K, Akimoto T, Kawabata K, Kishimoto S, Kitano H, Tohnai I, Nakatsuka T
Auris Nasus Larynx 2017 Aug;44(4):375-380. Epub 2017 Mar 18 doi: 10.1016/j.anl.2017.02.004. PMID: 28325607

Recent clinical studies

Therapy

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators
Lancet 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4. PMID: 34454674
Head and neck squamous cell carcinoma.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR
Nat Rev Dis Primers 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3. PMID: 33243986Free PMC Article
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr
J Clin Oncol 2020 Jan 1;38(1):1-10. Epub 2019 Nov 4 doi: 10.1200/JCO.19.02105. PMID: 31682550Free PMC Article
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL
J Immunother Cancer 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5. PMID: 31307547Free PMC Article
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group
N Engl J Med 2007 Oct 25;357(17):1695-704. doi: 10.1056/NEJMoa071028. PMID: 17960012

Prognosis

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Blum Murphy M, Amaya-Chanaga C, Patel A, Hu N, Matsumura Y, Kitagawa Y, Ajani J
Cancer Med 2024 May;13(9):e7235. doi: 10.1002/cam4.7235. PMID: 38716626Free PMC Article
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Ikeda G, Miyakoshi J, Yamamoto S, Kato K
Future Oncol 2024 Apr;20(11):665-677. Epub 2023 Dec 21 doi: 10.2217/fon-2022-1092. PMID: 38126175
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J
Eur J Cancer 2023 Apr;183:24-37. Epub 2023 Jan 9 doi: 10.1016/j.ejca.2022.12.015. PMID: 36796234
Head and neck squamous cell carcinoma.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR
Nat Rev Dis Primers 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3. PMID: 33243986Free PMC Article
Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S, Kato K
Expert Opin Biol Ther 2020 Oct;20(10):1143-1150. Epub 2020 Jul 14 doi: 10.1080/14712598.2020.1792881. PMID: 32620063

Clinical prediction guides

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Blum Murphy M, Amaya-Chanaga C, Patel A, Hu N, Matsumura Y, Kitagawa Y, Ajani J
Cancer Med 2024 May;13(9):e7235. doi: 10.1002/cam4.7235. PMID: 38716626Free PMC Article
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators
Lancet 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4. PMID: 34454674
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E
Lancet Oncol 2021 Apr;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3. PMID: 33794205
Head and neck squamous cell carcinoma.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR
Nat Rev Dis Primers 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3. PMID: 33243986Free PMC Article
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL
J Immunother Cancer 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5. PMID: 31307547Free PMC Article

Recent systematic reviews

A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
Jiménez-Labaig P, Rullan A, Hernando-Calvo A, Llop S, Bhide S, O'Leary B, Braña I, Harrington KJ
Cancer Treat Rev 2024 Jul;128:102772. Epub 2024 May 26 doi: 10.1016/j.ctrv.2024.102772. PMID: 38820656
p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis.
Su Y, Cui J, Xu D, Wang M, Xu T, Tian H, Han F
Crit Rev Oncol Hematol 2018 Apr;124:11-20. Epub 2018 Feb 7 doi: 10.1016/j.critrevonc.2018.02.006. PMID: 29548481
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, Macluskey M, Chan KK, Conway DI
Cochrane Database Syst Rev 2011 Apr 13;(4):CD006386. doi: 10.1002/14651858.CD006386.pub3. PMID: 21491393
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, Macluskey M, Chan KK, Conway DI; CSROC Expert Panel
Cochrane Database Syst Rev 2010 Sep 8;(9):CD006386. doi: 10.1002/14651858.CD006386.pub2. PMID: 20824847

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...